Omeros Corp - Company Profile
Powered by
All the data and insights you need on Omeros Corp in one report.
- Save hours of research time and resources with
our up-to-date Omeros Corp Strategy Report
- Understand Omeros Corp position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Omeros Corp (Omeros) is a biopharmaceutical company that discovers, develops and commercializes small-molecule and protein therapeutics for large-market and orphan indications. The company’s marketed product, Omidria is a phenylephrine and ketorolac injection for use during cataract surgery or replacement of intraocular lens (IOL). The company is investigating its product candidates for the use in arthroscopic, ophthalmological, and other surgical procedures including thrombotic microangiopathies, mediated glomerulopathies, addictive and compulsive disorders among others. It is also evaluating preclinical product candidates for treatment of alternative pathway disorders, central nervous system disorders, metabolic, oncologic, musculoskeletal and other disorders. Omeros is headquartered in Seattle, Washington, the US.
Omeros Corp premium industry data and analytics
Products and Services
Products | Brands |
---|---|
Omidria: Cataract Surgery or Intraocular Lens | Omidria |
Pipeline | Narsoplimab |
Narsoplimab- Renal diseases, COVID-19 | |
XYZ | |
XYZ | |
XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
Year | Event | Description |
---|---|---|
2023 | Others | In February, the company received US$200 million payment from Rayner Surgical. |
2022 | Regulatory Approval | In July, the company announced OMS906 received orphan drug designation from the U.S. Food and Drug Administration (FDA) for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). |
2022 | Regulatory Approval | In January, the company submitted to the U.S. Food and Drug Administration (FDA) its response regarding the BLA for Narsoplimab in the treatment of HSCT-TMA. |
Competitor Comparison
Key Parameters | Omeros Corp | Alexion Pharmaceuticals Inc | Seagen Inc | Harrow Inc | Akari Therapeutics Plc |
---|---|---|---|---|---|
Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
City | Seattle | Boston | Bothell | Nashville | Boston |
State/Province | Washington | Massachusetts | Washington | Tennessee | Massachusetts |
No. of Employees | 198 | 3,000 | 3,256 | 315 | 9 |
Entity Type | Public | Private | Private | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
Name | Position | Board | Since | Age |
---|---|---|---|---|
Gregory A. Demopulos, M.D. | Chief Executive Officer; President; Chairman | Executive Board | 2013 | 64 |
Michael A. Jacobsen | Treasurer; Vice President - Finance; Chief Accounting Officer | Senior Management | 2013 | 64 |
Andreas Grauer, M.D. | Chief Medical Officer | Senior Management | 2023 | - |
George A. Gaitanaris, M.D., Ph.D. | Chief Scientific Officer; Vice President - Science | Senior Management | 2012 | 66 |
Nadia Dac | Vice President; Chief Commercial Officer | Senior Management | 2021 | 53 |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward